Introduction
of cardiovascular death in those undergoing longterm dialysis. Cardiovascular disease accounts for half the deaths in adults treated with maintenance dialysis, and mortality from cardiovascular causes is far higher than that in Disturbances of calcium and phosphate metabolism the general population [1, 2] . Contributing factors and cardiovascular morbidity include sodium and water overload, hypertension, diabetes mellitus, alterations in lipid metabolism and Evidence is accumulating that disturbances in mineral elevated levels of homocysteine in serum [3] [4] [5] [6] [7] [8] . Despite metabolism contribute to the development of cardioconsiderable progress over the last two decades in the vascular disease and to overall mortality in patients management of these and other traditional cardiovaswith ESRD [11] [12] [13] [14] [15] . Block et al. reported that elevated cular risks, the mortality rate from cardiovascular serum phosphorus levels were an independent risk causes has not diminished in patients with end-stage factor for death in adults undergoing dialysis even renal disease ( ESRD) [9] . Indeed, cardiovascular morafter adjusting for established cardiovascular risks and tality for those treated with dialysis continues to far other co-morbid conditions [11] . The mechanisms that exceed that predicted from the combined risks attributunderlie this association remain uncertain, but hyperable to age, sex, systolic blood pressure, left ventricular phosphataemia has long been recognized as an importhypertrophy, serum total and HDL cholesterol, cigarant determinant of soft tissue and vascular calcification ette smoking and diabetes mellitus [10] . Other factors in patients with chronic renal failure. Several recent studies suggest that vascular calcification, due at least Correspondence and offprint requests to: Isidro B. Salusky, M.D., in part to hyperphosphataemia and/or the measures pathway by which alterations in mineral metabolism of mineral metabolism that result from chronic renal failure aggravate the deposition of calcium and phoscan adversely affect clinical outcomes both in adult and in paediatric patients with 16, 17] . phorus within existing atherosclerotic plaques. Alternatively, the two processes may be distinct and unrelated to one another. Considerable additional
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work is required to resolve this matter. noted that 65% of adult haemodialysis patients between ticularly important determinant of plaque fragility, leading to plaque rupture and thrombosis. Although the ages of 29 and 72 years had EBCT evidence or coronary artery calcification [30] . The results of three the relationship between vascular calcification and the atherosclerotic process is not fully understood, certain independent studies demonstrate that the extent of coronary calcification is substantially greater in factors that are integrally involved in mineral metabolism are known to influence the process of arterial wall patients with ESRD than that observed in patients of the same age and gender in the general population, calcification [22] [23] [24] [25] .
Calcium deposits in atherosclerotic plaques can con-including those with angiographically documented coronary artery disease [13, 30, 31] . tain hydroxyapatite, which represents the crystal phase of calcium and phosphorus in fully mineralized bone.
The observations by Guerin and co-workers [14] and by Eifinger et al. are consistent with data reported In some cases, advanced atherosclerotic lesions have fully formed bone elements within them, including recently by Goodman and colleagues in young adults treated with dialysis [13] . Nearly 90% of patients trabeculae, lacunae and areas resembling marrow spaces. Potential mediators of bone formation within between the ages of 20 and 30 had EBCT evidence of coronary artery calcification [13] . In contrast, only the arterial wall included developmental retention of pluripotent cells or osteoblastic immigration with loss three of 60 volunteers of the same age with normal renal function had any coronary artery calcification of regulatory control [23, 26 ] . Studies using in situ hybridization in calcified human atherosclerotic lesions that was detectable by EBCT [13] . Patients with positive scans were older, and they had been treated with have demonstrated expression of the bone-related proteins osteopontin and bone morphogenic protein type dialysis for much longer than those with negative scans. As such, the proportion of young adults with 2 (BMP-2) [23, 27] . It has also been shown that smooth muscle cells can calcify under certain in vitro cell coronary artery calcification increased as a function of the duration of treatment with dialysis [13] . Coronary culture conditions [28] , and vitamin D has been suggested to play a role in the development of vascular artery calcification scores nearly doubled when EBCT were repeated 18-24 months later. calcifications [29] .
Despite these findings, the relationship between Compared with those without EBCT evidence of coronary artery calcification, young adult with positive arterial calcification in chronic renal failure and the process of calcification within atherosclerotic lesion EBCT scans had higher serum phosphorus levels and higher values for the calcium-phosphorus ion product remains uncertain. It is possible that the abnormalities in serum. Both factors have previously been implicated cium are needed to effectively diminish intestinal phosphorus absorption. Indeed, the doses required far in the development of cardiac valve calcification in older adults with ESRD [20] . Perhaps more important, exceed the 1500 mg of elemental calcium that is recommended for persons with normal renal function to however, was the finding that young adult dialysis patients with coronary artery calcification were prevent age-related bone loss [43, 44] The new phosphate-binding agent, sevelamer phosphate restriction alone is only moderately effective in controlling serum phosphorus levels, and further (RenagelB), approved by the Food and Drug Administration ( FDA) in the United States, is an ion decreases in dietary phosphorus content compromise overall nutrition, particularly protein intake [34] . exchange resin that binds phosphorus in the intestinal lumen and prevents its absorption. It does not contain Phosphate removal during dialysis is limited largely due to the intracellular location of most inorganic either calcium or aluminium, and it has been shown to be effective in managing phosphate retention both phosphorus. The amounts removed either by thriceweekly haemodialysis,~800 mg/treatment or in short-term and long-term studies of patients undergoing haemodialysis [48] [49] [50] [51] . The cholesterol lowering 2400 mg/week, or by daily peritoneal dialysis, 300-400 mg/treatment or 2100-2800 mg/week, are far properties of this compound also make it an appealing therapeutic alternative for use in a subgroup of patients less than that ingested by most patients, 800-1200 mg/day or 5600 9600 mg/week [35] . The who are known to be at risk for developing cardiovascular disease [52] . inadequacy of current haemodialysis regimens for controlling serum phosphorus levels is underscored by the In addition to sevelamer, there are other ironcontaining compounds in different phases of drug finding that patients treated with daily nocturnal haemodialysis have normal serum phosphorus levels development, such as stabilized polynuclear iron hydroxide and ferric polymaltose complex, have been and often do not require oral phosphate-binding medications [36 ] .
shown to be effective in controlling serum phosphour levels in short-term studies in adults and rats with chronic renal failure [53, 54] . Another agent, lan-
The use of phosphate-binding agents thanum chloride hydrate, also decreases intestinal phosphorus absorption in experimental animals, and clinical trials using this compound are currently During the first two decades of treatment with maintenance dialysis in patients with end-stage renal disease, underway [55] .
When the treatment of secondary hyperparathyroidaluminium-containing compounds were used predominantly as phosphate-binding agents. Subsequently, the ism with vitamin D sterols is necessary, the use of new vitamin D analogues that putatively have less of an use of these compounds was associated with the development of aluminium toxicity because patients with effect in raising serum calcium and phosphorus levels should be considered to diminish the chances of develrenal failure cannot excrete aluminium that is absorbed from the gastrointestinal tract [37, 38] . As a result, oping hypercalcaemia and/or hyperphosphataemia.
These are often complications of calcitriol therapy, calcium-containing compounds have been widely used for the past decade as phosphate-binding agents both and their occurrence limits the dose of calcitriol that can be safely given [47] . The new vitamin D analogues in adults and in children undergoing regular dialysis [39] [40] [41] [42] . Unfortunately, quite large oral doses of cal-that are available for clinical use in the United States 
